SLC5A2 and metabolic dysfunction-associated steatotic liver disease: SGLT2 Inhibitors: A five-year retrospective study assessed the outcomes of long-term SGLT2 inhibition therapy (specifically canagliflozin) in patients with T2DM and NAFLD.